Company Update (NASDAQ:AMGN): European Commission Approves Amgen’s BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia

[PR Newswire] – THOUSAND OAKS, Calif., Nov. 24, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted conditional marketing authorization for BLINCYTO ® (blinatumomab) … Read more on . . . → Read More: Company Update (NASDAQ:AMGN): European Commission Approves Amgen’s BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s leukemia drug gets conditional European approval Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Company Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults